作者
Thomas Marron, Julia Kodysh, Alex Rubinsteyn, John Finnigan, Ana Blazquez, Mansi Saxena, Marcia Meseck, Timothy O’Donnell, Daniela Delbeau, Matthew Galsky, Deborah Doroshow, Brett Miles, Krysztof Misiukiewicz, Hanna Irie, Amy Tiersten, Samir Parekh, Marshall Posner, Andrea Wolf, John Mandeli, Jeffrey Hammerbacher, Michael Donovan, Rachel Brody, Sacha Gnjatic, Eric Schadt, Philip Friedlander, Nina Bhardwaj
发表日期
2020/11/1
来源
Journal for ImmunoTherapy of Cancer
卷号
8
期号
Suppl 3
出版商
BMJ Specialist Journals
简介
Background
The efficacy of T cell directed immunotherapies relies on adequate priming of T cells to tumor-specific neoantigens, which some studies have augmented with synthetic neoantigen vaccines. This is the first report of a personalized genomic vaccine (PGV-001) in multiple histologies in the adjuvant setting.
Methods
Tumor and germline RNA and DNA were sequenced, and neoantigen peptides were selected using our OpenVax custom computation pipeline that identifies and ranks mutant sequences by a combination of predicted MHC-I binding affinity and neoantigen abundance within tumor. Up to 10 peptides were synthesized per patient and were administered over the course of 27 weeks in combination with the poly-ICLC. Primary objectives were to determine 1) the safety and tolerability; 2) the feasibility of PGV-001 production and administration; and 3) the immunogenicity of PGV-001. Secondary …
学术搜索中的文章
T Marron, J Kodysh, A Rubinsteyn, J Finnigan… - 2020